86 related articles for article (PubMed ID: 24125980)
1. Evaluation of antitumor efficacy and toxicity of novel 6-nitro-2-(3-chloropropyl)-1H-benz[de]isoquinoline-1,3-dione in vivo in mouse.
Mukherjee A; Dutta S; Sanyal U
J Cancer Res Ther; 2013; 9(3):442-6. PubMed ID: 24125980
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
Mukherjee A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2007 Dec; 26(4):489-97. PubMed ID: 18365543
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of naphthal-NU, a 2-chloroethylnitrosourea derivative of naphthalimide, as a mixed-function anticancer agent.
Samanta S; Pain A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2002 Mar; 21(1):87-93. PubMed ID: 12071535
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Qazi GN; Sanyal U
J Exp Clin Cancer Res; 2003 Sep; 22(3):411-8. PubMed ID: 14582700
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent.
Samanta S; Pain A; Dutta S; Saxena AK; Shanmugavel M; Pandita RM; Qazi GN; Sanyal U
J Exp Ther Oncol; 2005; 5(1):15-22. PubMed ID: 16416597
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
7. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of toxicity of beta-tethymustine, a new anticancer compound, in mice.
Ghosh M; Sadhu U; Bhattacharya S; Dutta S; Bhattacharya B; Sanyal U
Cancer Lett; 1999 Apr; 138(1-2):107-14. PubMed ID: 10378781
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of fluoren-NU as a novel antitumor agent.
Mukherjee A; Dutta S; Chashoo G; Bhagat M; Saxena AK; Sanyal U
Oncol Res; 2009; 17(9):387-96. PubMed ID: 19718945
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of toxicity of cypenhymustine, a new anticancer compound, in mice.
Sadhu U; Ghosh M; Bhattacharya S; Dutta S; Das H; Sanyal U
Cancer Lett; 1994 Sep; 85(1):65-72. PubMed ID: 7923104
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma-180.
Bhattacharya S; Ghosh M; Sadhu U; Dutta S; Sanyal U
Neoplasma; 1996; 43(3):209-13. PubMed ID: 8841510
[TBL] [Abstract][Full Text] [Related]
13. Preliminary evaluation of in vitro cytotoxicity and in vivo antitumor activity of Premna herbacea Roxb. in Ehrlich ascites carcinoma model and Dalton's lymphoma ascites model.
Dhamija I; Kumar N; Manjula SN; Parihar V; Setty MM; Pai KS
Exp Toxicol Pathol; 2013 Mar; 65(3):235-42. PubMed ID: 21920724
[TBL] [Abstract][Full Text] [Related]
14. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Sharma M; Qazi GN; Sanyal U
Acta Pol Pharm; 2007; 64(1):27-33. PubMed ID: 17665847
[TBL] [Abstract][Full Text] [Related]
16. In vivo anti-tumour activity of novel Quinazoline derivatives.
Alapati V; Noolvi MN; Manjula SN; Pallavi KJ; Patel HM; Tippeswamy BS; Satyanarayana SV
Eur Rev Med Pharmacol Sci; 2012 Nov; 16(13):1753-64. PubMed ID: 23208959
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antitumor activity and in vivo antioxidant status of Anthocephalus cadamba on Ehrlich ascites carcinoma treated mice.
Dolai N; Karmakar I; Suresh Kumar RB; Kar B; Bala A; Haldar PK
J Ethnopharmacol; 2012 Aug; 142(3):865-70. PubMed ID: 22705911
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy and amelioration of oxidative stress by Trichosanthes dioica root against Ehrlich ascites carcinoma in mice.
Bhattacharya S; Prasanna A; Majumdar P; Kumar RB; Haldar PK
Pharm Biol; 2011 Sep; 49(9):927-35. PubMed ID: 21819262
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and antioxidant property of Curcuma caesia against Ehrlich's ascites carcinoma bearing mice.
Karmakar I; Dolai N; Suresh Kumar RB; Kar B; Roy SN; Haldar PK
Pharm Biol; 2013 Jun; 51(6):753-9. PubMed ID: 23527894
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
